Biotricity Inc (BTCY)

$1.24

+0.14

(+12.73%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Biotricity Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.89M → 2.97M (in $), with an average increase of 2.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.69M → -2.80M (in $), with an average increase of 31.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.0% return, outperforming this stock by 114.4%

Performance

  • $1.08
    $1.24
    $1.24
    downward going graph

    13.31%

    Downside

    Day's Volatility :13.31%

    Upside

    0.0%

    downward going graph
  • $0.70
    $4.37
    $1.24
    downward going graph

    43.49%

    Downside

    52 Weeks Volatility :83.97%

    Upside

    71.62%

    downward going graph

Returns

PeriodBiotricity IncIndex (Russel 2000)
3 Months
-0.01%
0.0%
6 Months
25.0%
0.0%
1 Year
-73.43%
0.0%
3 Years
-93.7%
-20.1%

Highlights

Market Capitalization
9.9M
Book Value
- $2.95
Earnings Per Share (EPS)
-1.75
PEG Ratio
0.0
Wall Street Target Price
4.0
Profit Margin
-125.43%
Operating Margin TTM
-43.11%
Return On Assets TTM
-95.17%
Return On Equity TTM
-4100.79%
Revenue TTM
11.6M
Revenue Per Share TTM
1.32
Quarterly Revenue Growth YOY
20.9%
Gross Profit TTM
4.6M
EBITDA
-9.2M
Diluted Eps TTM
-1.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.55
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Biotricity Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 222.58%

Current $1.24
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Biotricity Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biotricity Inc
Biotricity Inc
-24.65%
25.0%
-73.43%
-93.7%
-93.7%
Stryker Corporation
Stryker Corporation
0.86%
12.4%
15.49%
28.53%
77.74%
Boston Scientific Corp.
Boston Scientific Corp.
11.25%
36.51%
40.96%
76.8%
100.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.89%
34.72%
1.32%
-5.35%
56.97%
Abbott Laboratories
Abbott Laboratories
-3.84%
0.25%
-4.89%
-12.22%
35.01%
Medtronic Plc
Medtronic Plc
5.71%
8.68%
-4.84%
-33.51%
-4.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biotricity Inc
Biotricity Inc
NA
NA
0.0
-1.55
-41.01
-0.95
NA
-2.95
Stryker Corporation
Stryker Corporation
37.6
37.6
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.33
63.33
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.77
38.77
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.15
32.15
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
26.83
26.83
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biotricity Inc
Biotricity Inc
Buy
$9.9M
-93.7%
NA
-125.43%
Stryker Corporation
Stryker Corporation
Buy
$125.6B
77.74%
37.6
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$110.8B
100.56%
63.33
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.4B
56.97%
38.77
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.5B
35.01%
32.15
13.96%
Medtronic Plc
Medtronic Plc
Buy
$112.2B
-4.04%
26.83
13.0%

Institutional Holdings

  • Vanguard Group Inc

    1.08%

  • Geode Capital Management, LLC

    0.68%

  • AE Wealth Management LLC

    0.44%

  • State Street Corporation

    0.24%

  • HRT FINANCIAL LLC

    0.20%

  • BlackRock Inc

    0.14%

Company Information

biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. biotricity’s premier product is bioflux, an ecg monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. biolife helps users make lifestyle changes by combining medically relevant ecg data with social media interactivity and a lifestyle log. biotricity’s r&d continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

Organization
Biotricity Inc
Employees
55
CEO
Dr. Waqaas Al-Siddiq Ph.D.
Industry
Packaged Software

Discover More

FAQs